Abstract :
[en] This work aims to develop, validate and optimize the radiolabeling of Starch-Based Microparticles (SBMP) by 188Re and 68Ga in the form of ready-to-use radiolabeling kits, the ultimate goal being to obtain a unique theranostic vector for the treatment of Hepatocellular Carcinoma.
METHODS: Optimal labeling conditions and composition of freeze-dried kits were defined by monitoring the radiochemical purity while varying several parameters. In vitro stability studies were carried out, as well as an in vivo biodistribution as a preliminary approach with the intra-arterial injection of 68Ga radiolabeled SBMP into the hepatic artery of DENA-induced rats followed by PET/CT imaging.
RESULTS: Kits were optimized for 188Re and 68Ga with high and stable radiochemical purity (>95% and >98% respectively). The in vivo preliminary study was successful with more than 95% of activity found in the liver and mostly in the tumorous part.
CONCLUSION: SBMP are a promising theranostic agent for the Selective Internal Radiation Therapy of Hepatocellular carcinoma
Funders :
This work has been supported by a grant from the Ministère de l'Enseignement Supérieur et de la Recherche in the frame of the Erasmus Mundus Joint Doctorate NanoFar program (EV); and has been supported in part by a grant from the French National Agency for Research called "Investissements d'Avenir" Labex IRON n°ANR-11- LABX-0018-01 (FH, FL, OC). This work was authorized by Laboratoires Cyclopharma, through patent WO2009013358. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Scopus citations®
without self-citations
14
